Inactive Instrument

Neuropathix, Inc.

Equities

NPTX

US64132Q1094

Biotechnology & Medical Research

Kannalife, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 14, 2019 at 02:12 pm

Kannalife, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 49,291 compared to USD 30,006 a year ago. Operating loss was USD 503,173 compared to USD 85,884 a year ago. Net loss was USD 845,965 compared to USD 151,335 a year ago. Basic loss per share was USD 0.01 compared to Basic EPS of USD 0 a year ago.

Latest news about Neuropathix, Inc.

Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Neuropathix, Inc. announced that it has received $0.15 million in funding	22-03-20	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	21-08-12	CI
Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-06	CI
Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	21-02-09	CI
Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	21-01-12	CI
Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-06	CI
Kannalife, Inc. has Changed its Name to Neuropathix, Inc	20-11-05	CI
Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of Advisors	20-09-17	CI
Kannalife, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories	20-07-09	CI
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors	20-06-02	CI
Kannalife, Inc. announced that it expects to receive $0.156 million in funding	20-06-01	CI
Kannalife, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-14	CI
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD	20-04-14	CI
Kannalife, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Kannalife, Inc. announced that it expects to receive $0.2 million in funding	20-03-11	CI
Kannalife, Inc. Strengthens Intellectual Property Portfolio with New Chinese-Issued Patent	20-02-20	CI
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN	20-02-11	CI

Chart Neuropathix, Inc.

Duration

Period

More charts

Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.92%	118B
REGENERON PHARMACEUTICALS, INC.	+10.19%	106B
BIONTECH SE	-11.79%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.55%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.46%	14.03B
SAREPTA THERAPEUTICS, INC.	+15.29%	11.67B

Bio Therapeutic Drugs